China Medical System Holdings (China Medical System Holdings) 3-Year EBITDA Growth Rate : -1.40% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is China Medical System Holdings 3-Year EBITDA Growth Rate?

China Medical System Holdings's EBITDA per Share for the six months ended in Dec. 2023 was $0.04.

During the past 12 months, China Medical System Holdings's average EBITDA Per Share Growth Rate was -23.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -1.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Medical System Holdings was 39.70% per year. The lowest was -49.70% per year. And the median was 17.20% per year.

Competitive Comparison of China Medical System Holdings's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Medical System Holdings's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's 3-Year EBITDA Growth Rate falls into.

China Medical System Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

China Medical System Holdings (OTCPK:CHSYF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

China Medical System Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of China Medical System Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

China Medical System Holdings (China Medical System Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Medical System Holdings Ltd (OTCPK:CHSYF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

00867:Hong Kong 2M7C:Germany

Address

510 King’s Road, Unit 2106, 21st Floor, North Point, Island Place Tower, Hong Kong, HKG

Website

http://www.cms.net.cn

China Medical System Holdings Ltd is active in the healthcare segment. It is one of the leading China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil; Salofalk; Combizym; Ganfule Capsules; Xidakang; Hirudoid; and others. Geographically, it derives revenue from China.

China Medical System Holdings (China Medical System Holdings) Headlines

From GuruFocus

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug

By ACN Newswire • 08-27-2023

Gelonghui Reports CMS' Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

By ACN Newswire ACN Newswire • 12-20-2022

China Medical System Holdings Ltd (CHSYF): A Deep Dive into its Upcoming Dividend

By GuruFocus Research • 09-11-2023